Chinese biopharmaceutical company ImmVira Group announced on Sunday that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

According to the company, as of the data cut-off on 31 January 2026, the optimised dose of MVR-T3011 achieved a 100% complete response rate (CRR) in BCG-unresponsive carcinoma in situ (CIS) and a durable 90% recurrence-free survival (RFS) in papillary (Ta/T1) tumours.

The ongoing trial enrolled 46 patients in total with pathologically confirmed BCG-unresponsive high-risk NMIBC. The results demonstrate that MVR-T3011 achieved meaningful clinical efficacy and a favourable safety profile across both carcinoma in situ (CIS) and papillary (Ta/T1) disease settings.

Across all patients treated, MVR-T3011 also demonstrated a manageable safety profile consistent with prior observations. ImmVira also noted that the higher-dose cohort showed a safety profile consistent with the lower-dose cohort, with no Grade 4 or 5 TEAEs reported across either dose level, or no deaths attributable to treatment.